Mercaptophenyl naphthyl methane compounds and synthesis thereof

• US 7,250,446 B2
• Filed: 03/26/2004
• Issued: 07/31/2007
• Est. Priority Date: 03/31/2003
• Status: Active Grant

• Current Assignee: Council of Scientific & Industrial Research
• Original Assignee: Council of Scientific & Industrial Research
• Inventors: Jain, Girish Kumar, Kumar, Atul, Ray, Suprabhat, Sangita, , Murthy, Puvvada Sri Ramanchandra, Singh, Man Mohan
• Primary Examiner(s): McKane; Joseph K.
• Assistant Examiner(s): CHUNG, SUSANNAH LEE
• Application Number:
  US10/809,845
• Publication Number:
  US 20040229869A1
• Time in Patent Office: 1,222 Days
• Field of Search: 514/601, 564/102, 568/28
• US Class Current: 514/601
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 5/30 Oestrogens
• CPC Class Codes: C07C 317/22 with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
• CPC Class Codes: C07C 317/24 having sulfone or sulfoxide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
• CPC Class Codes: C07C 323/19 with singly-bound oxygen atoms bound to acyclic carbon atoms of the carbon skeleton
• CPC Class Codes: C07C 323/22 containing thio groups and doubly-bound oxygen atoms bound to the same carbon skeleton
• CPC Class Codes: C07C 323/25 the carbon skeleton being acyclic and saturated
• CPC Class Codes: C07D 295/088 to an acyclic saturated chain

Abstract

Novel mercaptophenyl naphthyl methane compounds, their pharmaceutically acceptable salts and compositions comprised thereof are useful for the prevention or treatment of various medical indications associated with estrogen dependent diseases or syndromes related to osteoporosis, bone loss, bone formation, cardiovascular disorders, neurodegenerative disorders, menopausal disorders, physiological disorders, diabetes disorders, prostatic carcinoma, cancer of breast, cancer of uterus, cancer of the cervix and cancer of the colon, threatened or habitual abortion, obesity, ovarian development or function, post-partum lactation and depression.

Claims

1. A mercaptophenyl naphthyl methane compound having the structural formula 1:

3. A mercaptophenyl naphthyl methane compound as defined by claim 1, wherein R is at the C-1 position of the naphthyl ring.

4. A mercaptophenyl naphthyl methane compound as defined by claim 1, wherein R is at the C-2 position of the naphthyl ring.

5. A mercaptophenyl naphthyl methane compound as defined by claim 1, which is:

(a) (4-Methylthiophenyl)-naphth-1-yl-carbinol;

(b) (4-Ethylthiophenyl)-naphth-1-yl-carbinol;

(c) (4-Methylsulfonylphenyl)-naphth-1-yl-carbinol;

(d) (4-Ethylsulfonylphenyl)-naphth-1-yl-carbinol;

or

(e) (4-Methylsulfonylphenyl)-naphth-2-yl-carbinol.

6. A method for the preparation of a mercaptophenyl naphthyl methane compound having the structural formula 1as claimed in claim 1 wherein R₃ is SCH₃, comprising the steps of:

(a) mixing α

or β

naphthoic acid with thioanisol in polyphosphoric acid at 70-120°

C. for 5-10 hrs to form a compound of formula;

7. The method as defined by claim 6, wherein formula 1, R is at the C-1 position of the naphthyl ring.

8. The method as defined by claim 6, wherein formula 1, R is at the C-2 position of the naphthyl ring.

9. The method as defined by claim 6, further comprising reacting the resultant compound of formula 1 in which R is CHOH, R₁ and R₂ are H and R₃ is SCH₃ with hydrogen peroxide in acetic acid under stirring for 8-10 hrs, to give a derivative of formula 1 wherein R is CHOH, R₁=R₂=H and R₃ is SO₂CH₃.

10. A method for the treatment of estrogen deficiency, osteoporosis, bone loss, bone formation, hyperlipidaemia or breast cancer comprising administering to a mammalian subject in need of such treatment, a thus effective amount of a mercaptophenyl naphthyl methane compound as defined by claim 1.

11. The method as defined by claim 10, comprising administering said compound as a pharmaceutical composition optionally alone or as acceptable salts via oral, systemic, local or topical delivery, intravenous, intra-arterial, intra-muscular, subcutaneous, intra-peritoneal, intra-dermal, buccal, intranasal, inhalation, vaginal, rectal, transdermal or any other suitable means in any conventional liquid or solid dosage form to achieve, conventional delivery, controlled delivery or targeted delivery, optionally along with pharmaceutical acceptable diluents, inorganic salts, excipients, glidants, lubricants, sweetening agents, wetting agents, absorbents or retardants.

12. The method as defined by claim 10, comprising administering said compound as gelatin capsules or compressed into tablets or pills or formulated in the form of lozenges, inclusion complexes with cyclodextrin derivatives, injectable depo formulations, aerosols, granules, powders, oral liquids, mucosal adhesive formulations, gel formulations, troches, elixirs, suspensions, syrups, wafers, liposomal delivery systems, implants, suppository, pessary, microemulsions, nanoemulsion, microparticles, nanoparticles, controlled release delivery systems, transdermal delivery systems, targeted delivery systems, conjugates with monoclonal antibodies or with other suitable carrier moieties.

13. The method as defined by claim 11, said pharmaceutical composition comprising inorganic salts selected from the group consisting of formate, acetate, phenyl acetate, trifluroacetate, acrylate, ascorbate, benzoate, chlorobenzoates, bromobezoates, iodobenzoates, nitrobenzoates, hydroxybenzoates, alkylbenzoates, alkyloxybenzoates, alkoxycarbonylbenzoates, naphthalene-2 benzoate, butyrates, phenylbutyrates, hydroxybutyrates, caprate, caprylate, cinnamate, mandelate, mesylate, citrate, tartarate, fumarate, heptanoate, hippurate, lactate, malate, maleate, malonate, nicotinate, isonicotinate, oxalate, phthalate, terephthalate, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate, propiolate, propionate, phenylpropionate, salicylate, sebacte, succinate, suberate, sulfate, bisulfate, pyrosulfate, sulfite, bisulfate, sulfonate, benzene sulfonate, bromobenzene sulfonates, chlorobenzene sulfonates, ethane sulfonates, methane sulfonates, naphthalene sulfonates, toluene sulfonates, and compounds thereof.

14. The method as defined by claim 11, said pharmaceutical composition comprising a pharmaceutically acceptable diluent selected from the group consisting of lactose, mannitol, sorbitol, microcrystalline cellulose, sucrose, sodium citrate, dicalcium phosphate, or any other ingredient of similar nature alone or in a suitable combination thereof;

binder selected from the group consisting of gum tragacanth, gum acacia, methyl cellulose, gelatin, polyvinyl pyrrolidone, starch or any other ingredient of similar nature alone or in a suitable combination thereof;

a disintegrating agent selected from the group consisting of agar-agar, calcium carbonate, sodium carbonate, silicates, alginic acid, corn starch, potato tapioca starch, primogel or any other ingredient of similar nature alone or in a suitable combination thereof;

a lubricant selected from the group consisting of magnesium stearate, calcium stearate or steorotes, talc, solid polyethylene glycols, sodium lauryl sulfate or any other ingredient of similar nature alone or in a suitable combination thereof;

a glidant selected from the group consisting of colloidal silicon dioxide or any other ingredient of similar nature alone or in a suitable combination thereof;

a sweetening agent selected from the group consisting of sucrose, saccharin or any other ingredient of similar nature alone or in a suitable combination thereof;

a flavoring agent selected from the group consisting of peppermint, methyl salicylate, orange flavor, vanilla flavor, or any other pharmaceutically acceptable flavor alone or in a suitable combination thereof;

a wetting agent selected from the group consisting of cetyl alcohol, glyceryl monostearate or any other pharmaceutically acceptable flavor alone or in a suitable combination thereof;

an absorbent selected from the group consisting of kaolin, bentonite clay or any other pharmaceutically acceptable flavor alone or in a suitable combination thereof;

a solution retarding agent selected from the group consisting of wax, paraffin or any other pharmaceutically acceptable flavor alone or in a suitable combination thereof.

15. The method as defined by claim 10, comprising administering about 0.1 mg to 1000 mg of said mercaptophenyl naphthyl methane compound.

16. The method as defined by claim 10, comprising administering about 0.5 mg to 500 mg of said mercaptophenyl naphthyl methane compound.

17. The method as defined by claim 10, comprising administering 1 mg to 100 mg of said mercaptophenyl naphthyl methane compound.

18. The method as defined by claim 10, comprising administering said mercaptophenyl naphthyl methane compound weekly, bi-weekly, daily or twice a day or three times a day, or in even more divided doses.

19. The method as defined by claim 10, comprising eliciting antiosteoporosis (antiresorptive) activity represented by T/C values in the range of about 0.1 to 0.8.

20. The method as defined by claim 19, comprising eliciting antiosteoporosis (antiresorptive) activity represented by T/C values in the range of about 0.3 to 0.6

21. The method as defined by claim 10, comprising enhancing bone mineral density (BMD) in the range of about 3-30%.

22. The method as defined by claim 21, comprising enhancing bone mineral density in the range of about 3.7-25%.

23. The method as defined by claim 10, comprising lowering total concentration of blood serum cholesterol by about 30%.

24. The method as defined by claim 23, comprising lowering total concentration of blood serum cholesterol by about 21%.

25. The method as defined by claim 10, comprising lowering tumor growth by about 30%.

26. The method as defined by claim 25, comprising lowering tumor growth by about 25%.

27. The method as defined by claim 10, comprising enhancing uterine weight in the range of about 12-45%.

28. The method as defined by claim 27, comprising enhancing uterine weight in the range of about 16-41%.

29. The method as defined by claim 10, comprising enhancing uterine morphometry (i.e., uterus and endometrium) in the range of about 0.05 to 1.5 mm².

30. The method as defined by claim 29, comprising enhancing uterine morphometry (i.e., uterus and endometrium) in the range of about 0.80 to 1.38 mm².

31. The method as defined by claim 10, comprising lowering relative binding affinity (RBA) to estrogen receptors by about <

0.001.

2. A mercaptophenyl naphthyl methane compound having the structural formula 1:

32. A pharmaceutical composition comprising a mercaptophenyl naphthyl methane compound having structural formula 1

33. The pharmaceutical composition as defined by claim 32, comprising:

(a) (4-Methylthiophenyl)-naphth-1-yl-carbinol;

(b) (4-Ethylthiophenyl)-naphth-1-yl-carbinol;

(c) (4-Methylsulfonylphenyl)-naphth-1-yl-carbinol;

(d) (4-Ethylsulfonylphenyl)-naphth-1-yl-carbinol;

or

(e) (4-Methylsulfonylphenyl)-naphth-2-yl-carbinol.

34. The pharmaceutical composition as defined by claim 32, wherein formula 1, R is at the C-1 position of the naphthyl ring.

35. The pharmaceutical composition as defined by claim 32, wherein formula 1, R is at the C-2 position of the naphthyl ring.

36. The pharmaceutical composition as defined by claim 32, formulated as gelatin capsules or compressed into tablets or pills, or formulated in the form of lozenges, inclusion complexes with cyclodextrin derivatives, injectable depo formulations, aerosols, granules, powders, oral liquids, mucosal adhesive formulations, gel formulations, troches, elixirs, suspensions, syrups, wafers, liposomal delivery systems, implants, suppository, pessary, microemulsions, nanoemulsion, microparticles, nanoparticles, controlled release delivery systems, transdermal delivery systems, targeted delivery systems, conjugates with monoclonal antibodies or with other suitable carrier moieties.

37. The pharmaceutical composition as defined by claim 32, comprising a pharmaceutically acceptable salt selected from the group consisting of formate, acetate, phenyl acetate, trifluroacetate, acrylate, ascorbate, benzoate, chlorobenzoates, bromobezoates, iodobenzoates, nitrobenzoates, hydroxybenzoates, alkylbenzoates, alkyloxybenzoates, alkoxycarbonylbenzoates, naphthalene-2 benzoate, butyrates, phenylbutyrates, hydroxybutyrates, caprate, caprylate, cinnamate, mandelate, mesylate, citrate, tartarate, fumarate, heptanoate, hippurate, lactate, malate, maleate, malonate, nicotinate, isonicotinate, oxalate, phthalate, terephthalate, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate, propiolate, propionate, phenylpropionate, salicylate, sebacte, succinate, suberate, sulfate, bisulfate, pyrosulfate, sulfite, bisulfate, sulfonate, benzene sulfonate, bromobenzene sulfonates, chlorobenzene sulfonates, ethane sulfonates, methane sulfonates, naphthalene sulfonates, toluene sulfonates, and compounds thereof.

38. The pharmaceutical composition as defined by claim 32, comprising a pharmaceutically acceptable diluent selected from the group consisting of a lactose, mannitol, sorbitol, microcrystalline cellulose, sucrose, sodium citrate, dicalcium phosphate, or any other ingredient of similar nature alone or in a suitable combination thereof;

binder selected from the group consisting of gum tragacanth, gum acacia, methyl cellulose, gelatin, polyvinyl pyrrolidone, starch or any other ingredient of similar nature alone or in a suitable combination thereof;

excipient selected from the group consisting of agar-agar, calcium carbonate, sodium carbonate, silicates, alginic acid, corn starch, potato tapioca starch, primogel or any other ingredient of similar nature alone or in a suitable combination thereof;

lubricant selected from the group consisting of a magnesium stearate, calcium stearate or steorotes, talc, solid polyethylene glycols, sodium lauryl sulfate or any other ingredient of similar nature alone or in a suitable combination thereof;

glidant selected from the group consisting of colloidal silicon dioxide or any other ingredient of similar nature alone or in a suitable combination thereof;

a sweetening agent selected from the group consisting of sucrose, saccharin or any other ingredient of similar nature alone or in a suitable combination thereof;

a flavoring agent selected from the group consisting of peppermint, methyl salicylate, orange flavor, vanilla flavor, or any other pharmaceutically acceptable flavor alone or in a suitable combination thereof;

wetting agent selected from the group consisting of acetyl alcohol, glyceryl monostearate or any other pharmaceutically acceptable flavor alone or in a suitable combination thereof;

absorbent selected from the group consisting of kaolin, bentonite clay or any other pharmaceutically acceptable flavor alone or in a suitable combination thereof;

retarding agent selected from the group consisting of wax, paraffin or any other pharmaceutically acceptable flavor alone or in a suitable combination thereof.

39. The pharmaceutical composition as defined by claim 32, comprising from 0.1 mg to 1000 mg of said compound of formula 1.

40. The pharmaceutical composition as defined by claim 32, comprising from 0.5 mg to 500 mg of said compound of formula 1.

41. The pharmaceutical composition as defined by claim 32, comprising from 1 mg to 100 mg of said compound of formula 1.

42. A mercaptophenyl maphthyl methane compound having the structural formula 1:

43. A mercaptophenyl naphthyl methane compound as defined by claim 42, wherein R is at the C-1 position of the naphthyl ring.

44. The mercaptophenyl naphthyl methane compound as defined by claim 42, which is (4-methylthiophenyl)-naphth-1-yl-carbinol.

45. A method for the treatment of estrogen deficiency, osteoporosis, bone loss, bone formation, hyperlipidaemia or breast cancer, comprising administering to a mammalian subject in need of such treatment, a thus effective amount of a mercaptophenyl naphthyl methane compound as defined by claim 42.

46. The method according to claim 45, wherein said compound is (4-methylthiophenyl)-naphth-1-yl-carbinol.

47. A pharmaceutical composition comprising a mercaptophenyl naphthyl methane compound having the structural formula 1:

48. The pharmaceutical composition as defined by claim 47, wherein R in the compound of formula 1 is at the C-1 position of the naphthyl ring.

49. The pharmaceutical composition as defined by claim 47, wherein the compound of formula 1 is (4-methylthiophenyl)-naphth-1-yl-carbinol.